BIOMAT Database Logo BIOMAT Database Logo

Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients. 1998

D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
First Pediatric Clinic, Aristotelian University of Thessaloniki, Greece.

Forty patients with beta-thalassemia major (BTM), between 11 and 19 years of age and maintained on long-term desferrioxamine (DFO) treatment, were examined by evoked potential and nerve conduction velocity studies to investigate a possible involvement of the auditory, visual, somatosensory, or peripheral nervous pathways. Pathologic findings in brainstem auditory-, visual-, and somatosensory-evoked potentials, and nerve conduction velocity studies were demonstrated in 25%, 15%, 7.5%, and 25% of the patients, respectively, whereas 15% demonstrated involvement of multiple neural pathways. Subclinical involvement of the auditory pathway was statistically associated with higher mean daily DFO dose and longer duration of DFO therapy, whereas abnormalities regarding the somatosensory pathways were related to older age, longer mean duration of DFO therapy, and lower serum copper levels. Involvement of the peripheral nervous system was related to lower serum copper levels. Multiple involvement of neural pathways was related to longer mean duration of DFO therapy. We conclude that risk factors related to long-term DFO treatment are only partly responsible for the subclinical involvement of neural pathways demonstrated in beta-thalassemia major patients.

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D008297 Male Males
D009431 Neural Conduction The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus. Nerve Conduction,Conduction, Nerve,Conduction, Neural,Conductions, Nerve,Conductions, Neural,Nerve Conductions,Neural Conductions
D001933 Brain Stem The part of the brain that connects the CEREBRAL HEMISPHERES with the SPINAL CORD. It consists of the MESENCEPHALON; PONS; and MEDULLA OBLONGATA. Brainstem,Truncus Cerebri,Brain Stems,Brainstems,Cerebri, Truncus,Cerebrus, Truncus,Truncus Cerebrus
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005071 Evoked Potentials Electrical responses recorded from nerve, muscle, SENSORY RECEPTOR, or area of the CENTRAL NERVOUS SYSTEM following stimulation. They range from less than a microvolt to several microvolts. The evoked potential can be auditory (EVOKED POTENTIALS, AUDITORY), somatosensory (EVOKED POTENTIALS, SOMATOSENSORY), visual (EVOKED POTENTIALS, VISUAL), or motor (EVOKED POTENTIALS, MOTOR), or other modalities that have been reported. Event Related Potential,Event-Related Potentials,Evoked Potential,N100 Evoked Potential,P50 Evoked Potential,N1 Wave,N100 Evoked Potentials,N2 Wave,N200 Evoked Potentials,N3 Wave,N300 Evoked Potentials,N4 Wave,N400 Evoked Potentials,P2 Wave,P200 Evoked Potentials,P50 Evoked Potentials,P50 Wave,P600 Evoked Potentials,Potentials, Event-Related,Event Related Potentials,Event-Related Potential,Evoked Potential, N100,Evoked Potential, N200,Evoked Potential, N300,Evoked Potential, N400,Evoked Potential, P200,Evoked Potential, P50,Evoked Potential, P600,Evoked Potentials, N100,Evoked Potentials, N200,Evoked Potentials, N300,Evoked Potentials, N400,Evoked Potentials, P200,Evoked Potentials, P50,Evoked Potentials, P600,N1 Waves,N2 Waves,N200 Evoked Potential,N3 Waves,N300 Evoked Potential,N4 Waves,N400 Evoked Potential,P2 Waves,P200 Evoked Potential,P50 Waves,P600 Evoked Potential,Potential, Event Related,Potential, Event-Related,Potential, Evoked,Potentials, Event Related,Potentials, Evoked,Potentials, N400 Evoked,Related Potential, Event,Related Potentials, Event,Wave, N1,Wave, N2,Wave, N3,Wave, N4,Wave, P2,Wave, P50,Waves, N1,Waves, N2,Waves, N3,Waves, N4,Waves, P2,Waves, P50
D005073 Evoked Potentials, Somatosensory The electric response evoked in the CEREBRAL CORTEX by stimulation along AFFERENT PATHWAYS from PERIPHERAL NERVES to CEREBRUM. Somatosensory Evoked Potentials,Evoked Potential, Somatosensory,Somatosensory Evoked Potential

Related Publications

D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Long-term desferrioxamine therapy in thalassemia.
January 1974, Annals of the New York Academy of Sciences,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Neurophysiologic and intellectual evaluation of beta-thalassemia patients.
January 2006, Brain & development,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Neurophysiologic study of beta-thalassemia patients.
October 1993, Journal of child neurology,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
January 1988, Birth defects original article series,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
[Long-term effects of combined therapy in patients with beta-thalassemia major].
January 1998, La Pediatria medica e chirurgica : Medical and surgical pediatrics,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
May 1991, Acta neurologica Scandinavica,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
November 1981, European journal of pediatrics,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
April 2004, Haematologica,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
October 1995, Seminars in hematology,
D I Zafeiriou, and A A Kousi, and C T Tsantali, and E E Kontopoulos, and P A Augoustidou-Savvopoulou, and P D Tsoubaris, and M A Athanasiou
Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
January 2002, Acta haematologica,
Copied contents to your clipboard!